Table 3 Univariate analysis for event-free and overall survival.

From: ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease

Variable

EFS

OS

HR

95% CI

P

HR

95% CI

P

Race

      

White

1

–

 

1

–

 

Black

0.62

0.14–2.69

0.523

0.64

0.15–2.76

0.546

Other

1.94

0.45–8.42

0.375

2.42

0.55–10.56

0.241

Ethnicity

      

Non-Hispanic

1

–

 

1

–

 

Hispanic

2.30

0.54–9.87

0.250

2.21

0.51–9.50

0.275

Germline BRCA1/2 mutation

      

Yes

1

–

 

1

–

 

No

0.64

0.15–2.81

0.554

0.62

0.14–2.71

0.518

T stage

      

1-2

1

–

 

1

–

 

3-4

3.56

1.51–8.38

0.004

4.38

1.84–10.43

0.001

Nodal status

      

Negative

1

–

 

1

–

 

Positive

3.61

1.46–8.96

0.006

2.72

1.13–6.56

0.026

TNM stage

      

I

1

–

 

1

–

 

II

2.01

0.26–15.90

0.507

1.82

0.23–14.38

0.571

III

8.97

1.16–69.60

0.036

8.11

1.05–62.90

0.023

RCB classa

      

II

1

–

 

1

–

 

III

6.58

2.48–17.48

<0.001

3.95

1.51–10.31

0.005

Adjuvant chemotherapy

      

Yes

1

–

 

1

–

 

No

0.85

0.36–2.00

0.711

0.86

0.37–2.03

0.736

ctDNA status

      

Negative

1

–

 

1

–

 

Positive

4.68

1.93–11.33

0.001

3.57

1.50–8.50

0.004

  1. Univariate analysis of EFS and OS based on clinicopathologic variables and ctDNA status.
  2. P is from Cox proportional hazards regression.
  3. aThere were no EFS events in RCB-I patients.
Back to article page